Gomes, Sara http://orcid.org/0000-0002-9086-2303
Garrido, Alicia http://orcid.org/0000-0003-0652-6348
Tonelli, Francesca http://orcid.org/0000-0002-4600-6630
Obiang, Donina
Tolosa, Eduardo
Martí, Maria José
Ruiz-Martínez, Javier
Vinagre-Aragón, Ana
Hernandez-Eguiazu, Haizea
Croitoru, Ioana
Marshall, Vicky L.
Koenig, Theresa http://orcid.org/0000-0002-7904-8482
Hotzy, Christoph
Hsieh, Frank
Sakalosh, Marianna
Tengstrand, Elizabeth
Padmanabhan, Shalini
Merchant, Kalpana http://orcid.org/0000-0003-1118-9403
Bruecke, Christof
Pirker, Walter
Zimprich, Alexander
Sammler, Esther http://orcid.org/0000-0003-3218-7116
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson’s Research (MJFF-020316, MJFF-009262)
Michael J. Fox Foundation for Parkinson’s Research
Chief Scientist Office (CAF/18/01)
Article History
Received: 22 November 2022
Accepted: 27 February 2023
First Online: 4 April 2023
Competing interests
: F.H., E.T., M.S. and K.M. declare no competing non-financial interests but the following competing financial interests: F.H., E.T., and M.S. are employed by Nextcea, Inc., which holds patent rights to the di-22:6-BMP and 2,2′-di-22:6-BMP biomarkers for neurological diseases involving lysosomal dysfunction (US 8,313,949, Japan 5,702,363, and Europe EP2419742). K.M. is a paid advisor to the Michael J Fox Foundation. The remaining authors declare no competing interests.